Skip to main content

FRI0390 DUKE-3: A 15-week open-label trial of pegloticase in refractory gout including patients with solid organ transplant or prior pegloticase treatment

Publication ,  Conference
Sundy, JS; Gansen, N; Kelly, S; Scarlett, E; Jaggers, D; Hershfield, MS
Published in: Annals of the Rheumatic Diseases
June 2013

Duke Scholars

Published In

Annals of the Rheumatic Diseases

DOI

EISSN

1468-2060

ISSN

0003-4967

Publication Date

June 2013

Volume

71

Issue

Suppl 3

Start / End Page

446.2 / 446

Publisher

Elsevier BV

Related Subject Headings

  • Arthritis & Rheumatology
  • 3204 Immunology
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
  • 1107 Immunology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sundy, J. S., Gansen, N., Kelly, S., Scarlett, E., Jaggers, D., & Hershfield, M. S. (2013). FRI0390 DUKE-3: A 15-week open-label trial of pegloticase in refractory gout including patients with solid organ transplant or prior pegloticase treatment. In Annals of the Rheumatic Diseases (Vol. 71, pp. 446.2-446). Elsevier BV. https://doi.org/10.1136/annrheumdis-2012-eular.2847
Sundy, J. S., N. Gansen, S. Kelly, E. Scarlett, D. Jaggers, and M. S. Hershfield. “FRI0390 DUKE-3: A 15-week open-label trial of pegloticase in refractory gout including patients with solid organ transplant or prior pegloticase treatment.” In Annals of the Rheumatic Diseases, 71:446.2-446. Elsevier BV, 2013. https://doi.org/10.1136/annrheumdis-2012-eular.2847.
Sundy JS, Gansen N, Kelly S, Scarlett E, Jaggers D, Hershfield MS. FRI0390 DUKE-3: A 15-week open-label trial of pegloticase in refractory gout including patients with solid organ transplant or prior pegloticase treatment. In: Annals of the Rheumatic Diseases. Elsevier BV; 2013. p. 446.2-446.
Sundy, J. S., et al. “FRI0390 DUKE-3: A 15-week open-label trial of pegloticase in refractory gout including patients with solid organ transplant or prior pegloticase treatment.” Annals of the Rheumatic Diseases, vol. 71, no. Suppl 3, Elsevier BV, 2013, pp. 446.2-446. Crossref, doi:10.1136/annrheumdis-2012-eular.2847.
Sundy JS, Gansen N, Kelly S, Scarlett E, Jaggers D, Hershfield MS. FRI0390 DUKE-3: A 15-week open-label trial of pegloticase in refractory gout including patients with solid organ transplant or prior pegloticase treatment. Annals of the Rheumatic Diseases. Elsevier BV; 2013. p. 446.2-446.

Published In

Annals of the Rheumatic Diseases

DOI

EISSN

1468-2060

ISSN

0003-4967

Publication Date

June 2013

Volume

71

Issue

Suppl 3

Start / End Page

446.2 / 446

Publisher

Elsevier BV

Related Subject Headings

  • Arthritis & Rheumatology
  • 3204 Immunology
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
  • 1107 Immunology
  • 1103 Clinical Sciences